No results for ‘’
Sun Pharma Advanced Research Company Ltd
NSE: SPARC BSE: 532872
₹204.22
(0.83%)
Mon, 15 Jun 2026, 06:25 pm
Market Cap (in Cr)6678.65
PE Ratio4.27
Dividend0
Health Technology
Pharmaceuticals: Major
24.5KCompany History
2007
- Sun Pharma Advanced Research Co.Ltd was formed.
- Sun Pharma Advanced Research Company Ltd allotted 3,39,441 equity shares to the bond-holders of Sun Pharma Industries Ltd.
- The Balance Sheet along with the Profit and Loss Account for the year ended March 31, 2007 was adopted.
- Mr. Dilip S Shanghvi and Mr. Sudhir V Valia were re-appointed as the Directors of the Company.
2011
- Sun Pharma announced USFDA approval for DOCEFREZ (docetaxel) for Injection.
2012
- SPARC's Starhaler Device was a finalist at Medical Design Excellence Awards.
- Sun Pharma Advanced Research Company Ltd issued rights in the ratio of 1:7.
2013
- SPARC provided an update on NCE & NDDS programs.
2014
- SPARC announced India approval for Paclitaxel Injection Concentrate for Nanodispersion.
2017
- SPARC received a Complete Response Letter from the USFDA for its New Drug Application for Elepsia XRTM, Levetiracetam extended-release tablets 1000 mg and 1500 mg.
2018
- SPARC provided progress on R&D Pipeline.
- Sun Pharma and SPARC announced US FDA Approval of XELPROS to treat Open-angle Glaucoma or Ocular Hypertension.
- SPARC announced top-line results of pivotal bioequivalence study for Paclitaxel Injection Concentrate for Suspension.
- Schrödinger and SPARC announced collaboration to accelerate Neurodegeneration Drug Development Program.
2019
- SPARC entered into a licensing agreement with Bioprojet to acquire exclusive rights for investigational medicinal product, SCD-044.
- SPARC entered into a licensing agreement with Bioprojet to acquire exclusive rights for investigational medicinal product.
- HitGen and SPARC entered into a DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration.
- SPARC received Orphan Drug Designation from the USFDA for SCO-088 for the treatment of patients with Chronic Myeloid Leukemia.
- SPARC entered into a licensing deal with CMS.
2020
- Sun Pharma Advanced Research Company Ltd granted an exclusive license to Tripoint Therapeutics LLC to commercialize ElepsiaTM XR 1000 mg and ElepsiaTM XR 1500 mg tablets in the USA.
- Sun Pharma Advanced Research Company Ltd got positive top-line results from its Phase 3 trial for its investigational drug, SDN-037, for the treatment of Inflammation and Pain associated with Ocular Surgery.
- SPARC provided an update on Clinical Programs and R&D Pipeline.
2021
- SPARC entered into a licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target.
- Sun Pharma Advanced Research Company Ltd granted exclusive worldwide rights to Visiox Pharma LLC for the development and commercialization of PDP-716 and SDN-037.
2022
- Sun Pharma and SPARC entered into a license agreement for commercialization of phenobarbital for injection in the US.
2023
- Sun Pharma Advanced Research Company Ltd entered into a licensing agreement to acquire exclusive rights for SCD-153.
- Sun Pharma Advanced Research Company Ltd formed a US subsidiary.